# Dividend Stocks Outperforming Market in 2026

> Johnson & Johnson and Amgen lead dividend stocks with strong growth potential despite near-term challenges.
- Title: Dividend Stocks Outperforming Market in 2026 · The Motley Fool
- Summary: Johnson & Johnson and Amgen lead dividend stocks with strong growth potential despite near-term challenges. Johnson & Johnson and Amgen offer stable dividend…
- Keywords: jnj, amgen, dividend stocks, s&p 500, market crash, regulatory pressure, clinical trials, finance, money, Dividend, Stocks, Outperforming
- Source: The Motley Fool — https://fool.com/investing/2026/10/20/2-dividend-stocks-crushing-the-market-in-2026-and
- Author: Prosper Junior Bakiny
- Published: 2026-10-20T20:40:00+00:00
- Read time: 1 min
- Topics: jnj, amgen, dividend stocks, s&p 500, market crash, regulatory pressure, clinical trials, finance, money
## Market Resilience and Risks
Broader equities remain resilient despite potential macroeconomic problems and geopolitical tensions leading to market crashes.
## Johnson & Johnson Overview
Johnson & Johnson outperformed the market this year with strong financial results but faces medtech challenges including a Class 1 recall for Impella heart pump.
## Johnson & Johnson's Medtech Issues
Johnson & Johnson's cardiovascular segment faces lower demand due to safety and efficacy questions with Impella heart pump under Class 1 recall in the U.S.
## Johnson & Johnson's Growth Drivers
Johnson & Johnson's innovative medicines segment shows growth potential with new products like ICOTYDE for plaque psoriasis and OTTAVA robotic-assisted surgery system.
## Johnson & Johnson's Dividend Safety
Johnson & Johnson has 64 years of consecutive dividend increases with a 1.93% dividend yield and AAA rating from S&P Global.
## Amgen's Regulatory Challenges
Amgen faces regulatory pressure on Tavneos due to safety risks and insufficient efficacy evidence with U.S. Food and Drug Administration pushing for removal from market.
## Amgen's Revenue and Growth
Amgen reported second-quarter revenue of $10.1 billion with 10% year-over-year growth despite losing U.S. patent exclusivity for denosumab.
## Amgen's Future Prospects
Amgen's pipeline includes promising candidates like MariTide for weight loss and Tezspire for asthma with strong long-term growth potential.
## Key takeaway

Johnson & Johnson and Amgen offer stable dividend growth with long-term resilience amid regulatory and market headwinds.